Related Experiment Video
Updated: Jan 22, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Acute Myeloid Leukemia Acquiring Promyelocytic Leukemia-Retinoic Acid Receptor Alpha at Relapse
Varsha Gupta1, Mohammed Shariff1, Ravneet Bajwa1
1Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Abstract:
Acute promyelocytic leukemia (APL) is identified as the M3 subtype of acute myeloid leukemia (AML). APL is presently one of the most curable leukemias. We describe here a rare case of APL who presented as a relapsed disease after 1 year of chemotherapy for AML. The patient lacked t(15;17) at the initial presentation but was present later at the time of relapse. The patient attained a complete remission following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide-based therapy. We discuss the possible mechanism behind secondary acquisition of promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) at relapse of AML. We also briefly discuss the clinical features, diagnosis and treatment of APL.
Insights
This study reports a rare case of acute promyelocytic leukemia (APL) relapsing after AML chemotherapy. The patient achieved remission with ATRA and arsenic trioxide therapy after secondary PML-RARA acquisition.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) with a high cure rate.
- Standard chemotherapy for AML was administered to a patient with a rare presentation of the disease.
- The genetic hallmark of APL, the t(15;17) translocation, was absent at initial diagnosis.
Observation:
- A patient initially diagnosed with AML relapsed after one year of chemotherapy.
- The relapsed disease exhibited the characteristic t(15;17) translocation, forming the PML-RARA fusion gene.
- This genetic abnormality was not detected at the time of the initial AML diagnosis.
Findings:
- The patient achieved complete remission after treatment with all-trans retinoic acid (ATRA) and arsenic trioxide.
- The secondary acquisition of the PML-RARA fusion gene at relapse is a key finding.
- This suggests a potential mechanism for disease evolution in certain AML cases.
Implications:
- This case highlights the importance of reassessing genetic profiles at relapse in AML.
- Understanding the secondary acquisition of PML-RARA may lead to novel therapeutic strategies for APL.
- Further research into the mechanisms of secondary genetic alterations in leukemia is warranted.
More Related Videos
Related Concept Videos
G-protein Coupled Receptors
Receptor-mediated Endocytosis
Amino acids
Internal Receptors
The Citric Acid Cycle
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

